1
Yoshiro Niitsu, Victor Knopov, Joseph E Payne, Richard P Witte, Mohammad Ahmadian, Loren A Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu: Retinoid-liposomes for treating fibrosis. Nitto Denko Corporation, Baker & Hostetler, June 3, 2014: US08741867 (7 worldwide citation)

What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID ...


2
Yoshiro Niitsu, Victor Knopov, Joseph E Payne, Richard P Witte, Mohammad Ahmadian, Loren A Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu: Retinoid-liposomes for enhancing modulation of HSP47 expression. Nitto Denko Corporation, Baker & Hostetler, March 4, 2014: US08664376 (6 worldwide citation)

What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1—2 (SEQ ID NOS: 60 and 127), SERPINH1—45a (SEQ ID ...


3
Yoshiro Niitsu, Victor Knopov, Joseph E Payne, Zheng Hou, John A Gaudette, Violetta Akopian, Richard P Witte, Mohammad Ahmadian, Loren A Perelman, Yasunobu Tanaka, Priya Karmali, Sridhar C Nagarajan: Cationic lipids for therapeutic agent delivery formulations. Nitto Denko Corporation, Baker & Hostetler, April 21, 2015: US09011903 (5 worldwide citation)

Here described are compounds of formula I: wherein R1 and R2 is independently selected from a group consisting of C10 to C18 alkyl, C12 to C18 alkenyl, and oleyl group; wherein R3 and R4 are independently selected from a group consisting of C1 to C6 alkyl, and C2 to C6 alkanol; wherein X is selected ...


4
Yoshiro Niitsu, Victor Knopov, Joseph E Payne, Richard P Witte, Mohammad Ahmadian, Loren A Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu: Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier. Nitto Denko Corporation, Baker & Hostetler, October 4, 2016: US09456984 (4 worldwide citation)

What is described is a method for treating a fibrotic disease by administering a pharmaceutical composition comprising a drug carrier, which comprises a lipid and a retinoid, and a double-stranded nucleic acid molecule, which comprises an antisense sequence to mRNA encoding human hsp47.


5
Yoshiro Niitsu, Joseph E Payne, John A Gaudette, Zheng Hou, Victor Knopov, Richard P Witte, Mohammad Ahmadian, Loren A Perelman, Yasunobu Tanaka, Violetta Akopian: Compounds for targeting drug delivery and enhancing siRNA activity. Nitto Denko Corporation, Baker & Hostetler, July 19, 2016: US09393315 (4 worldwide citation)

Here described are compounds consisting of the structure (targeting molecule)m-linker-(targeting molecule)n, wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker com ...


6
Yoshiro Niitsu, Victor Knopov, Joseph E Payne, Zheng Hou, John A Gaudette, Violetta Akopian, Richard P Witte, Mohammad Ahmadian, Loren A Perelman, Yasunobu Tanaka, Priya Karmali, Sridhar C Nagarajan: Cationic lipids for therapeutic agent delivery formulations. NITTO DENKO CORPORATION, Baker & Hostetler, January 26, 2016: US09242001 (4 worldwide citation)

Here described are compounds of formula I: wherein R1 and R2 is independently selected from a group consisting of C10 to C18 alkyl, C12 to C18 alkenyl, and oleyl group; wherein R3 and R4 are independently selected from a group consisting of C1 to C6 alkyl, and C2 to C6 alkanol; wherein X is selected ...


7
Yoshiro Niitsu, Victor Knopov, Joseph E Payne, Zheng Hou, John A Gaudette, Violetta Akopian, Richard P Witte, Mohammad Ahmadian, Loren A Perelman, Yasunobu Tanaka, Priya Karmali, Sridhar C Nagarajan: Cationic lipids for therapeutic agent delivery formulations. Nitto Denko Corporation, Baker & Hostetler, May 8, 2018: US09963424 (2 worldwide citation)

Here described are compounds of formula I: wherein R1 and R2 are independently selected from C10 to C18 alkyl, C12 to C18 alkenyl, and oleoyl; R3 and R4 are independently selected from C1 to C6 alkyl and C2 to C6 alkanol; X is selected from —CH2—, —S—, and —O—, or X is absent; Y is selected from —(C ...


8
Nicholas D Cosford, Thomas J Seiders, Joseph E Payne, Jeffrey R Roppe, Dehua Huang, Nicholas D Smith, Steve F Poon, Chris King, Brian W Eastman, Bowei Wang, Jeannie M Arruda, Jean Michel Vernier, Xiumin Zhao: Thiazolyl mglur5 antagonists and methods for their use. Merck Sharp & Dohme, J Eric Thies, Gerald M Devlin, February 1, 2011: US07879882 (2 worldwide citation)

The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selecti ...


9
Joseph E Payne, Padmanabh Chivukula, David Webb: Lipid particles with asymmetric cationic lipids for RNA delivery. Arcturus Therapeutics, Baker & Hostetler, February 28, 2017: US09580711 (1 worldwide citation)

What is described is a lipid particle comprising the compound of formula I wherein R1 consists of alkyl, alkenyl, alkynyl, or cholesteryl; R2 consists of alkyl or alkenyl; L1 consists of alkyl, alkylene or alkenyl; X1 consists of —O—(CO)— or —(CO)—O—; X2 consists of S or O; L2 consists of a bond or ...


10
Yoshiro Niitsu, Victor Knopov, Joseph E Payne, Richard P Witte, Mohammad Ahmadian, Loren A Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu, Zheng Hou, John A Gaudette, Priya Karmali, Sridhar C Nagarajan: Retinoid-lipid drug carrier. Nitto Denko Corporation, Baker & Hostetler, February 5, 2019: US10196637

What is described is a pharmaceutical composition for treating a fibrotic disease comprising a drug carrier, which comprises a lipid and a retinoid, and a double-stranded nucleic acid molecule, which comprises an antisense sequence to mRNA encoding human hsp47.